JAMA Oncology Author Interviews
JAMA Network
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
Episodes
Mentioned books
Jun 24, 2021 • 13min
Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
May 13, 2021 • 19min
Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases
Interview with David R. Raleigh, MD, PhD, and William C. Chen, MD, authors of Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases: A Systematic Review and Meta-analysis
Apr 15, 2021 • 15min
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC
Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Mar 25, 2021 • 18min
Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
Interview with Douglas B. Johnson, MD, author of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
Feb 18, 2021 • 30min
Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase
Interview with Luc GT Morris, MD MSc, author of Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase
Jan 7, 2021 • 24min
Virtual Care Across a Tertiary Cancer Center During COVID-19
Interview with Alejandro Berlin, MD, MSc, author of Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19
Dec 17, 2020 • 13min
Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases
Interview with Catherine Van Poznak, MD, author of Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer
Nov 12, 2020 • 15min
Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Interview with Ehab Atallah, MD, author of Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial
Oct 8, 2020 • 14min
Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia
Interview with Farhad Ravandi, MD, author of Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis
Sep 17, 2020 • 23min
Survival and Adjuvant Chemotherapy in Early-Stage NSCLC With vs Without Clinicopathologic Features
Interview with Daniel J Boffa, MD, author of Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
